KRAS and neoplasm: Therefore, we modulated TRPC1 level in different CRC cell lines (HCT116 cell line with KRAS mutation, SW620 cell line with KRAS and PIK3CA mutations, and HT29 cell line with BRAF and PIK3CA mutations) and found that the knockdown of TRPC1 reduced cell proliferation, cell-cycle progression, invasion, and migration in vitro, and inhibited tumor growth of the xenograft mice models.